Covid Inquiry: Abuse of experts must stop, says Whitty
Sir Chris laments treatment as he gives evidence to Covid Inquiry on pandemic preparedness.
Similar Posts
Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug | Reuters News Agency
Health 25 August 2023, 6:39 pm 1 minute Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but…
Do You Have Peeing Issues? These Foods And Drinks May Be To Blame.
You’re likely familiar with foods that aren’t good for your heart. But when it comes to your bladder, it’s possible that you haven’t considered the correlation between diet and peeing. Unless you’ve had a urinary tract infection, suffered from a leaky bladder, or experienced the need to pee frequently, it may not have crossed your…
Fauci admits social distancing not based on science, ‘sort of just appeared’
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Covid and flu winter jabs to be brought forward in England
As in previous years, the NHS will let people know when bookings open. Adult flu and COVID-19 appointments will be available through the NHS App and website, or by calling 119 for those who can’t get online. Flu vaccines will also be available through local GP practices and pharmacies. Flu vaccinations for children which will…
NHS whole-gene screening helps tailor cancer care
How cutting-edge cancer genomics is now being used in mainstream cancer care.
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…
